Cardiac resynchronization therapy

Series
Cardiac electrophysiology
Status
Published
Date
Number of report
045

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for cardiac resynchronization therapy.

Sample pages are provided for an older version of the report. Before delivery to the client, the report is updated to the current state (e.g., 2022 coding, tariffs, and policy considerations). 

Both Cardiac Resynchronization Therapy Pacemaker (CRT-P) and Cardiac Resynchronization Therapy Defibrillator (CRT-D) are considered.

Reimbursement analysis will cover the following procedures:

  • Implantation of CRT system
  • Replacement of CRT system
  • Removal of CRT system

The following indications will be considered:

  • Congestive heart failure
  • Ventricular tachycardia

The only reimbursement within public / statutory health insurance systems is considered.

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of devices for cardiac resynchronization system (CRT and CRT-D) include:

  • Abbott Vascular (Quadra Allure, Quadra Assura)
  • Biotronik (Inventra 7HF-T, Intica CRT-DX ProMRI, Ilvia -HF-T QP ProMRI, Etrinsa 8HF-T, Edora 8 HF-T QP)
  • Boston Scientific (Dynagen X4, Inogen, Momentum, Resonate, Vigilant, Valitude X4, Intua, Invive)
  • MicroPort (Reply, Platinium)

Table of content is not available at the moment. Report is still ongoing.

12

Oct 2022

In September 2022, the French National Authority for Health (HAS) published four new opinions, which were based on health technology assessment reports. They are related to neuromodulation and cardiovascular areas. The main goal of these HTAs was to support decision-making for the creation of new procedure codes in the Common Classification of Medical Procedures (CCAM) and to update the indications for implantable cardiac defibrillators with endocavitary lead(s) in the Intra-DRG list.

Read more

14

Sep 2022

The French National Authority for Health (HAS) released new recommendations about transitional coverage of medical devices from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in August 2022. One opinion was published regarding the cardiac resynchronization system WISE CRT-SYSTEM by EBR System.

Read more

18

Aug 2022

On July 15, 2022, the Austrian Institute for HTA (AIHTA) published five decision support documents, which provide recommendations regarding the inclusion of new medical interventions in the catalog of individual medical services of the performance-oriented hospital financing (Leistungsorientierten Krankenanstaltenfinanzierung, LKF) model, as well as four updates to previous decision support documents. The decisions relate mainly to cardiovascular and gastrointestinal technology groups.

Read more

25

Apr 2022

On March 31, 2022, NHS Digital released HRG4+ Local Payment Grouper for 2022/23 for use from April 01, 2022. In general, there are significant changes in base HRG design. A total of 120 new HRGs were created, and multiple HRGs were removed, so the total number increased by 62 from 2,838 to 2,900.

Read more

14

Feb 2022

On January 28, 2022, the Institute for the Hospital Remuneration System (InEK) has published the list of the requests for innovation funding (NUB) that were submitted by the hospitals in 2021. The medical technologies belonging to the cardiovascular, ENT, eHealth, gastrointestinal, neuromodulation, neurovascular, orthopedic, and other technology groups obtained positive status 1.

Read more
(we accept only company emails)